HUP0203650A2 - Heterociklusos származékok, eljárás az előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

Heterociklusos származékok, eljárás az előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP0203650A2
HUP0203650A2 HU0203650A HUP0203650A HUP0203650A2 HU P0203650 A2 HUP0203650 A2 HU P0203650A2 HU 0203650 A HU0203650 A HU 0203650A HU P0203650 A HUP0203650 A HU P0203650A HU P0203650 A2 HUP0203650 A2 HU P0203650A2
Authority
HU
Hungary
Prior art keywords
compound
preparation
pharmaceutical compositions
compositions containing
heterocyclic derivatives
Prior art date
Application number
HU0203650A
Other languages
English (en)
Inventor
Alessandra Orlandi
Original Assignee
Glaxo Wellcome S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome S.P.A. filed Critical Glaxo Wellcome S.P.A.
Publication of HUP0203650A2 publication Critical patent/HUP0203650A2/hu
Publication of HUP0203650A3 publication Critical patent/HUP0203650A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A találmány az (I) képletű 7-klór-4-(1-fenil-2-oxo-3-pirrolidinilidén)-1,2,3,4-tetrahidro-2-ki- nolinkarbonsav A.enantiomerének az új megluminsójára vagy ennek egy szolvátjára, avegyület előállítási eljárásaira, a vegyületet tartalmazógyógyszerkészítményekre, valamint a vegyület gyógyászatifelhasználására, különösen az NMDA receptor komplexen lévő excitációs(izgató) aminosavak hatásainak az antagonizálására szolgálógyógyszerként történő alkalmazására vonatkozik. Ó
HU0203650A 1999-12-08 2000-12-07 Heterocyclic derivatives, process for their preparation, pharmaceutical compositions containing them and their use HUP0203650A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9929037.1A GB9929037D0 (en) 1999-12-08 1999-12-08 Heterocyclic derivatives
PCT/EP2000/012335 WO2001042238A1 (en) 1999-12-08 2000-12-07 Heterocyclic derivatives

Publications (2)

Publication Number Publication Date
HUP0203650A2 true HUP0203650A2 (hu) 2003-03-28
HUP0203650A3 HUP0203650A3 (en) 2004-01-28

Family

ID=10865952

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203650A HUP0203650A3 (en) 1999-12-08 2000-12-07 Heterocyclic derivatives, process for their preparation, pharmaceutical compositions containing them and their use

Country Status (30)

Country Link
US (2) US6713491B2 (hu)
EP (1) EP1237886B1 (hu)
JP (1) JP4311901B2 (hu)
KR (1) KR100788579B1 (hu)
CN (1) CN1325488C (hu)
AR (1) AR030923A1 (hu)
AT (1) ATE323691T1 (hu)
AU (1) AU769232B2 (hu)
BR (1) BR0016235A (hu)
CA (1) CA2393303C (hu)
CO (1) CO5251474A1 (hu)
CY (1) CY1106105T1 (hu)
CZ (1) CZ301052B6 (hu)
DE (1) DE60027461T2 (hu)
DK (1) DK1237886T3 (hu)
ES (1) ES2257343T3 (hu)
GB (1) GB9929037D0 (hu)
HK (1) HK1047436B (hu)
HU (1) HUP0203650A3 (hu)
IL (2) IL150010A0 (hu)
MX (1) MXPA02005802A (hu)
MY (1) MY129892A (hu)
NO (1) NO323263B1 (hu)
PL (1) PL356713A1 (hu)
PT (1) PT1237886E (hu)
TN (1) TNSN00240A1 (hu)
TR (1) TR200201503T2 (hu)
TW (1) TW524804B (hu)
WO (1) WO2001042238A1 (hu)
ZA (1) ZA200204492B (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100506811C (zh) * 2003-04-25 2009-07-01 日本化学医药株式会社 (2s,3s)-3-[[(1s)-1-异丁氧基甲基-3-甲基丁基]氨基甲酰基]环氧乙烷-2-甲酸盐
GB0327912D0 (en) * 2003-12-02 2004-01-07 Glaxo Group Ltd Medicament
US7576216B2 (en) * 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
EP1802607A2 (en) 2004-10-08 2007-07-04 Abbott Laboratories Salt and crystalline forms thereof of a drug
DK1868581T3 (da) * 2005-04-11 2012-07-09 Abbott Lab Farmaceutiske sammensætninger med forbedrede opløsningsprofiler til dårligt opløselige lægemidler
ES2689481T3 (es) 2011-10-25 2018-11-14 Janssen Pharmaceutica Nv Formulaciones de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5529999A (en) 1994-03-04 1996-06-25 Eli Lilly And Company Antitumor compositions and methods of treatment
US6413959B1 (en) * 1995-04-14 2002-07-02 Boehringer Ingelheim Kg Method of treating depression with arylglycinamide derivatives
DK0854867T3 (da) 1995-09-29 2002-12-02 Glaxosmithkline Spa Tetrahydroquinoliner som NMDA-antagonister
GB9617305D0 (en) 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
TR200201503T2 (tr) 2002-10-21
EP1237886A1 (en) 2002-09-11
DK1237886T3 (da) 2006-08-14
ES2257343T3 (es) 2006-08-01
US6713491B2 (en) 2004-03-30
MXPA02005802A (es) 2004-08-12
CN1407980A (zh) 2003-04-02
HK1047436B (zh) 2006-07-21
TW524804B (en) 2003-03-21
KR20020086854A (ko) 2002-11-20
US6943176B2 (en) 2005-09-13
IL150010A (en) 2009-09-01
BR0016235A (pt) 2002-08-27
HUP0203650A3 (en) 2004-01-28
AU2006001A (en) 2001-06-18
DE60027461T2 (de) 2006-09-28
JP4311901B2 (ja) 2009-08-12
ATE323691T1 (de) 2006-05-15
CO5251474A1 (es) 2003-02-28
PL356713A1 (en) 2004-06-28
CN1325488C (zh) 2007-07-11
US20040162313A1 (en) 2004-08-19
JP2003516403A (ja) 2003-05-13
NO20022682L (no) 2002-07-17
AR030923A1 (es) 2003-09-03
DE60027461D1 (de) 2006-05-24
ZA200204492B (en) 2004-06-30
CA2393303C (en) 2009-10-20
CZ301052B6 (cs) 2009-10-21
IL150010A0 (en) 2002-12-01
GB9929037D0 (en) 2000-02-02
MY129892A (en) 2007-05-31
AU769232B2 (en) 2004-01-22
WO2001042238A1 (en) 2001-06-14
US20030008899A1 (en) 2003-01-09
CA2393303A1 (en) 2001-06-14
TNSN00240A1 (en) 2002-05-30
NO323263B1 (no) 2007-02-19
HK1047436A1 (en) 2003-02-21
NO20022682D0 (no) 2002-06-06
PT1237886E (pt) 2006-07-31
KR100788579B1 (ko) 2007-12-26
EP1237886B1 (en) 2006-04-19
CZ20021981A3 (cs) 2003-01-15
CY1106105T1 (el) 2011-06-08

Similar Documents

Publication Publication Date Title
AU2003240680A1 (en) 1h-imidazo(4,5-c) quinoline derivatives in the treatment of protein kinase dependent diseases
PL1687305T3 (pl) Pochodne 1H-imidazochinolin jako inhibitory kinaz białkowych
HUP0301213A2 (hu) Ciklin dependens kinázok amino-tiazol inhibitorai, ezeket tartalmazó gyógyszerkészítmények, előállításuk és alkalmazásuk
HUP0103542A2 (hu) Opioid-receptor aktivitással rendelkező 4,4-biaril-piperidin származékok és a vegyületeket tartalmazó gyógyászati készítmények
HUP0301195A2 (hu) Alfa-4 integrin antagonista hatású aza-hidas biciklusos aminosav-származékok és ilyen vegyületeket tartalmazó gyógyszerkészítmények
HUP0000720A2 (hu) Imidazo [1,2-a] piridinszármazékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP9603237A2 (hu) (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzizotiazol-2-il)-butil]-amino-metil}-kromán kristályos hidrokloridja, eljárás előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0103063A2 (hu) Új 2H-piridazin-származékok, alkalmazásuk, ilyen hatóanyagot tartalmazó gyógyászati készítmények, és eljárás a hatóanyag előállítására
BRPI0409427A (pt) composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
HUP0001922A2 (hu) Pirazolo[4,3-c]-piridin származékok, ezeket tartalmazó inzulinrezisztencia elleni gyógyszerkészítmények, intermedierek és eljárás előállításukra
CA2136553A1 (en) 7-(2-aminoethyl)-Benzothiazolones
HUP0401080A2 (hu) Új görcsoldó sószármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP9802121A2 (hu) Imidazolinszármazékok, eljárás előállításukra és e vegyületeket tartalmazó gyógyszerkészítmények
HUT57763A (en) Process for producing 2,9-disubstituted-4h-pyrido(1,2-a)pyrimidine-4-one derivatives and pharmaceutical compositions comprising such compounds as active ingredient
HUP0203650A2 (hu) Heterociklusos származékok, eljárás az előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0402602A2 (hu) Eljárás echinokandin-származékok előállítására, ezek alkalmazása, ezeket tartalmazó gyógyszerkészítmények és intermedierek
HUP9802897A2 (hu) Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény
HUP0402038A2 (hu) 2-Amino-4-heteroaril-etil-tiazolin-származékok alkalmazása az indukálható NO-szintetáz inhibitoraként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE69104220T2 (de) Verfahren zur Herstellung von direktkomprimierten, Cephalosporansäure Derivate enthaltendenTabletten.
AP9901659A0 (en) Quinoline-2-carboxylic acid derivatives and its use as excitatory amino acids antagonist.
HUP0303676A2 (hu) Helyettesített 4-fenil-1-(1-fenil-ciklohexil)-1,2,3,6-tetrahidropiridinek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
AP9801417A0 (en) Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders.
HUP0000307A2 (hu) Y Neuropeptid antagonisták és ezeket tartalmazó gyógyászati készítmények
HUP0300191A2 (hu) 2,6-Diamino-6-metil-heptánsav és származékai, eljárás ezek előállítására és alkalmazásuk
HUP0400304A2 (hu) Dihidroimidazo[5,1-a]-béta-karbolin-származékok, előállításuk és gyógyszerként való alkalmazásuk

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees